U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 10 of 11 results

Status:
US Approved Rx (2016)
First approved in 2016

Class (Stereo):
CHEMICAL (ACHIRAL)



Rucaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of advanced mutant BRCA ovarian cancer. Rucaparib is being investigated in clinical trials against prostate cancer, breast cancer and other neoplasms.
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)



The dihydrochloride salt of nolatrexed, a water-soluble lipophilic quinazoline folate analog with antineoplastic activity. Nolatrexed occupies the folate binding site of thymidylate synthase, resulting in inhibition of thymidylate synthase activity a...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)

Metesind (AG-331) is a lipophilic thymidylate synthase inhibitor. It inhibits the cofactor binding site of the enzyme. It exerts cytotoxic properties. Metesind was being developed as an anticancer and antimetabolite agent.
Status:
Investigational

Class (Stereo):
CHEMICAL (ABSOLUTE)



Rupintrivir is a peptide aldehyde that targets the human rhinovirus (HRV) 3C proteinase enzyme and has the potential for the treatment of the common cold. Rupintrivir is derived from AG-6084 - in order to develop human rhinovirus 3C protease inhibito...
Status:
Investigational

Class (Stereo):
CHEMICAL (ABSOLUTE)



Prinomastat is a synthetic hydroxamic acid derivative with potential antineoplastic activity. Prinomastat inhibits matrix metalloproteinases (MMPs) (specifically, MMP-2, 9, 13, and 14), thereby inducing extracellular matrix degradation, and inhibitin...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)

Agouron (Pfizer) was developing AG-24322 (AG-024322), a small-molecule cyclin-dependent kinase (CDK) inhibitor, for the treatment of cancer. AG-024322 is a potent inhibitor of CDK1, CDK2, and CDK4 that produces cell-cycle arrest and antitumor activit...
Status:
US Approved Rx (2016)
First approved in 2016

Class (Stereo):
CHEMICAL (ABSOLUTE)



Rucaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of advanced mutant BRCA ovarian cancer. Rucaparib is being investigated in clinical trials against prostate cancer, breast cancer and other neoplasms.
Status:
US Approved Rx (2016)
First approved in 2016

Class (Stereo):
CHEMICAL (ACHIRAL)



Rucaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of advanced mutant BRCA ovarian cancer. Rucaparib is being investigated in clinical trials against prostate cancer, breast cancer and other neoplasms.
Status:
Investigational

Class (Stereo):
CHEMICAL (ABSOLUTE)



Prinomastat is a synthetic hydroxamic acid derivative with potential antineoplastic activity. Prinomastat inhibits matrix metalloproteinases (MMPs) (specifically, MMP-2, 9, 13, and 14), thereby inducing extracellular matrix degradation, and inhibitin...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)



The dihydrochloride salt of nolatrexed, a water-soluble lipophilic quinazoline folate analog with antineoplastic activity. Nolatrexed occupies the folate binding site of thymidylate synthase, resulting in inhibition of thymidylate synthase activity a...

Showing 1 - 10 of 11 results